Advertisement

Angiotensin-Converting Enzyme Inhibitor Use and Incident Frailty: A Longitudinal Cohort Study

  • Nicola VeroneseEmail author
  • Brendon Stubbs
  • Lee Smith
  • Stefania Maggi
  • Sarah E. Jackson
  • Pinar Soysal
  • Jacopo Demurtas
  • Stefano Celotto
  • Ai Koyanagi
Original Research Article

Abstract

Introduction

Angiotensin-converting enzyme inhibitors (ACEI) may have several pleiotropic effects, but the literature regarding a possible relationship between ACEI use and frailty is limited. We investigated whether ACEI use is associated with lower risk of frailty in a cohort of North American individuals.

Methods

Data from the Osteoarthritis Initiative, a cohort study with 8 years of follow-up including community-dwelling adults with knee osteoarthritis or at high risk for this condition, were analyzed. ACEI use was defined through self-reported information and confirmed by a trained interviewer. Frailty was defined using the Study of Osteoporotic Fracture (SOF) index as the presence of at least two of the following criteria: (1) weight loss ≥ 5% between baseline and any subsequent follow-up visit; (2) inability to do five chair stands; and (3) low energy level according to the SOF definition. A multivariable Poisson regression analysis was used to assess the association between ACEI use at baseline and incident frailty. The data were reported as relative risks (RRs) with their 95% confidence intervals (CIs).

Results

The final sample consisted of 4295 adults (mean age 61.2 years, females 58.1%). At baseline, 551 participants (12.8%) used ACEI. After adjusting for 15 potential confounders, the use of ACEI was associated with a lower risk of frailty (RR 0.72; 95% CI 0.53–0.99). The adjustment for the propensity score substantially confirmed these findings (RR 0.75; 95% CI 0.54–0.996).

Conclusion

ACEI use may be associated with a reduced risk of frailty in individuals with/at risk of knee osteoarthritis, suggesting a potential role for ACI in the prevention of frailty.

Notes

Compliance with Ethical Standards

Funding

This study was funded by five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) from the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation, GlaxoSmithKline; and Pfizer, Inc. Private-sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners.

Conflict of interest

Veronese, Stubbs, Smith, Maggi, Jackson, Soysal, Demurtas, Celotto and Koyanagi declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.

REFERENCES

  1. 1.
    Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411–20.CrossRefGoogle Scholar
  2. 2.
    Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting–enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333(25):1670–6.CrossRefGoogle Scholar
  3. 3.
    Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–8.CrossRefGoogle Scholar
  4. 4.
    Cranney A. Is there a new role for angiotensin-converting-enzyme inhibitors in elderly patients? CMAJ Can Med Assoc J. 2007;177(8):891–2.CrossRefGoogle Scholar
  5. 5.
    Ashdown-Franks G, Stubbs B, Koyanagi A, Schuch F, Firth J, Veronese N, et al. Handgrip strength and depression among 34,129 adults aged 50 years and older in six low- and middle-income countries. J Affect Disord. 2019;15(243):448–54.CrossRefGoogle Scholar
  6. 6.
    Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. Can Med Assoc J. 2007;177(8):867–74.CrossRefGoogle Scholar
  7. 7.
    Hutcheon S, Gillespie N, Crombie I, Struthers A, McMurdo M. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart (British Cardiac Society). 2002;88(4):373–7.CrossRefGoogle Scholar
  8. 8.
    Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet (London, England). 2013;381(9868):752–62.CrossRefGoogle Scholar
  9. 9.
    Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012;60(8):1487–92.CrossRefGoogle Scholar
  10. 10.
    Kojima G. Prevalence of frailty in nursing homes: a systematic review and meta-analysis. J Am Med Dir Assoc. 2015;16(11):940–5.CrossRefGoogle Scholar
  11. 11.
    Veronese N, Cereda E, Stubbs B, Solmi M, Luchini C, Manzato E, et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: results from a meta-analysis and exploratory meta-regression analysis. Ageing Res Rev. 2017;28(35):63–73.CrossRefGoogle Scholar
  12. 12.
    Rizzoli R, Reginster JY, Arnal JF, Bautmans I, Beaudart C, Bischoff-Ferrari H, et al. Quality of life in sarcopenia and frailty. Calcif Tissue Int. 2013;93(2):101–20.CrossRefGoogle Scholar
  13. 13.
    Robine J-M, Michel J-P. Looking forward to a general theory on population aging. J Gerontol Ser A Biol Sci Med Sci. 2004;59(6):M590–7.CrossRefGoogle Scholar
  14. 14.
    Gray SL, LaCroix AZ, Aragaki AK, McDermott M, Cochrane BB, Kooperberg CL, et al. Angiotensin-converting enzyme inhibitor use and incident frailty in women aged 65 and older: prospective findings from the Women’s Health Initiative Observational Study. J Am Geriatr Soc. 2009;57(2):297–303.CrossRefGoogle Scholar
  15. 15.
    Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet (London, England). 2002;359(9310):926–30.CrossRefGoogle Scholar
  16. 16.
    Eby GA, Eby KL. Rapid recovery from major depression using magnesium treatment. Med Hypotheses. 2006;67(2):362–70.CrossRefGoogle Scholar
  17. 17.
    Veronese N, Stubbs B, Noale M, Solmi M, Pilotto A, Vaona A, et al. Polypharmacy is associated with higher frailty risk in older people: an 8-year longitudinal cohort study. J Am Med Dir Assoc. 2017;18:624–8.CrossRefGoogle Scholar
  18. 18.
    Bolzetta F, Wetle T, Besdine R, Noale M, Cester A, Crepaldi G, et al. The relationship between different settings of medical service and incident frailty. Exp Gerontol. 2018;15(108):209–14.CrossRefGoogle Scholar
  19. 19.
    Veronese N, Stubbs B, Maggi S, Notarnicola M, Barbagallo M, Firth J, et al. Dietary magnesium and incident frailty in older people at risk for knee osteoarthritis: an eight-year longitudinal study. Nutrients. 2017;9(11):E1253.CrossRefGoogle Scholar
  20. 20.
    Misra D, Felson DT, Silliman RA, Nevitt M, Lewis CE, Torner J, et al. Knee osteoarthritis and frailty: findings from the Multicenter Osteoarthritis Study and Osteoarthritis Initiative. J Gerontol Ser A Biol Sci Med Sci. 2015;70(3):339–44.CrossRefGoogle Scholar
  21. 21.
    Veronese N, Cereda E, Solmi M, Fowler SA, Manzato E, Maggi S, et al. Inverse relationship between body mass index and mortality in older nursing home residents: a meta-analysis of 19,538 elderly subjects. Obes Rev. 2015;16(11):1001–15.CrossRefGoogle Scholar
  22. 22.
    Ware J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;34(3):220–33.CrossRefGoogle Scholar
  23. 23.
    Allen KD, Golightly YM. Epidemiology of osteoarthritis: state of the evidence. Curr Opin Rheumatol. 2015;27(3):276–83.CrossRefGoogle Scholar
  24. 24.
    Lewinsohn PM, Seeley JR, Roberts RE, Allen NB. Center for Epidemiologic Studies Depression Scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging. 1997;12(2):277–87.CrossRefGoogle Scholar
  25. 25.
    Washburn RA, McAuley E, Katula J, Mihalko SL, Boileau RA. The physical activity scale for the elderly (PASE): evidence for validity. J Clin Epidemiol. 1999;52(7):643–51.CrossRefGoogle Scholar
  26. 26.
    Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care. 1996;34(1):73–84.CrossRefGoogle Scholar
  27. 27.
    Veronese N, Koyanagi A, Stubbs B, Cooper C, Guglielmi G, Rizzoli R, et al. Statin use and knee osteoarthritis outcomes: a longitudinal cohort study. Arthritis Care Res. 2018;1:1.  https://doi.org/10.1002/acr.23735.Google Scholar
  28. 28.
    Miles J. Tolerance and variance inflation factor. Wiley StatsRef: Statistics Reference Online; 2009.Google Scholar
  29. 29.
    Haukoos JS, Lewis RJ. The Propensity Score. JAMA. 2015;314(15):1637–8.CrossRefGoogle Scholar
  30. 30.
    Gutiérrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero Á, Inzitari M, Martínez-Velilla N. The relationship between frailty and polypharmacy in older people: a systematic review. Br J Clin Pharmacol. 2018;84(7):1432–44.CrossRefGoogle Scholar
  31. 31.
    Veronese N, Stubbs B, Noale M, Solmi M, Pilotto A, Vaona A, et al. Polypharmacy is associated with higher frailty risk in older people: an 8-year longitudinal cohort study. J Am Med Dir Assoc. 2017;18(7):624–8.CrossRefGoogle Scholar
  32. 32.
    Kitakaze M, Node K, Minamino T, Asanuma H, Ueda Y, Kosaka H, et al. Inhibition of angiotensin-converting enzyme increases the nitric oxide levels in canine ischemic myocardium. J Mol Cell Cardiol. 1998;30(11):2461–6.CrossRefGoogle Scholar
  33. 33.
    Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev. 2001;81(1):209–37.CrossRefGoogle Scholar
  34. 34.
    Koh TJ, Tidball JG. Nitric oxide synthase inhibitors reduce sarcomere addition in rat skeletal muscle. J Physiol. 1999;519(1):189–96.CrossRefGoogle Scholar
  35. 35.
    Kortekaas KE, Meijer CA, Hinnen JW, Dalman RL, Xu B, Hamming JF, et al. ACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm. PLoS One. 2014;9(12):e111952.CrossRefGoogle Scholar
  36. 36.
    Soysal P, Stubbs B, Lucato P, Luchini C, Solmi M, Peluso R, et al. Inflammation and frailty in the elderly: a systematic review and meta-analysis. Ageing Res Rev. 2016;31:1–8.CrossRefGoogle Scholar
  37. 37.
    Bano G, Trevisan C, Carraro S, Solmi M, Luchini C, Stubbs B, et al. Inflammation and sarcopenia: a systematic review and meta-analysis. Maturitas. 2017;96:10–5.CrossRefGoogle Scholar
  38. 38.
    Barberi L, Scicchitano BM, Musarò A. Molecular and cellular mechanisms of muscle aging and sarcopenia and effects of electrical stimulation in seniors. Eur J Transl Myol. 2015;25(4):231–6.CrossRefGoogle Scholar
  39. 39.
    Ferder L, Inserra F, Romano L, Ercole L, Pszenny V. Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse. Am J Physiol. 1993;265(1 Pt 1):C15–8.CrossRefGoogle Scholar
  40. 40.
    Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Nicola Veronese
    • 1
    Email author
  • Brendon Stubbs
    • 2
    • 3
    • 4
  • Lee Smith
    • 5
  • Stefania Maggi
    • 1
  • Sarah E. Jackson
    • 6
  • Pinar Soysal
    • 7
  • Jacopo Demurtas
    • 8
  • Stefano Celotto
    • 9
  • Ai Koyanagi
    • 10
    • 11
  1. 1.National Research Council, Neuroscience Institute, Aging BranchPaduaItaly
  2. 2.Physiotherapy DepartmentSouth London and Maudsley NHS Foundation TrustLondonUK
  3. 3.Health Service and Population Research Department, Institute of Psychiatry, Psychology and NeuroscienceKing’s College LondonLondonUK
  4. 4.Faculty of Health, Social Care and EducationAnglia Ruskin UniversityChelmsfordUK
  5. 5.The Cambridge Centre for Sport and Exercise SciencesAnglia Ruskin UniversityCambridgeUK
  6. 6.Department of Behavioural Science and HealthUniversity College LondonLondonUK
  7. 7.Department of Geriatric Medicine, Faculty of MedicineBezmialem Vakif UniversityIstanbulTurkey
  8. 8.Primary Care DepartmentAzienda USL Toscana Sud EstGrossetoItaly
  9. 9.Primary Care DepartmentAziendale AAS3 Alto Friuli, Collinare, Medio FriuliUdineItaly
  10. 10.Research and Development Unit, Parc Sanitari Sant Joan de DéuUniversitat de Barcelona, Fundació Sant Joan de DéuBarcelonaSpain
  11. 11.Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAMMadridSpain

Personalised recommendations